Where Will Geovax Labs Inc (GOVX) Stock Go Next After It Is Down 0.68% in a
Overall market sentiment has been high on Geovax Labs Inc (GOVX) stock lately. GOVX receives a Bullish rating from InvestorsObserver’s Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What’s Happening With GOVX Stock Today?
Geovax Labs Inc (GOVX) stock is down -5.02% while the S&P 500 is higher by 0.35% as of 1:03 PM on Thursday, Apr 8. GOVX has fallen -$0.23 from the previous closing price of $4.58 on volume of 128,449 shares. Over the past year the S&P 500 has gained 53.95% while GOVX is higher by 13.87%. GOVX lost -$2.14 per share in the over the last 12 months.
More About Geovax Labs Inc
Geovax Labs Inc is US-based clinical-stage biotechnology company. It is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a novel patented Modified Vaccinia Ankara-Virus Like Particle (GV-MVA-VLP) vector vaccine platform. The development programs of the company focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The product pipeline includes HIV-Clade B Preventive Vaccine, HIV-Clade B Immunotherapy, Hemorrhagic Fever Vaccines, Zika Vaccine, Malaria vaccine, and Cancer Immunotherapy.